1974
Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance
Mason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaPlatelet countGranulocytic leukemiaClinical significanceOccurrence of thrombocytosisElevated platelet countThrombohemorrhagic complicationsUntreated patientsMedian durationShorter survivalBlastic crisisNormal countsPatientsSubsequent courseThrombocytosisLeukemiaCountEntire courseGroupCourseComplicationsClinicIncidenceDiagnosis
1973
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply